Cargando…
Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease
BACKGROUND: The first case of Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were diagnosed in Wuhan, China in 2019. In the first half of 2020 this disease has already converted into a global pandemic. Various treatment options were being tried all over the world. Some s...
Autores principales: | Fatima, Syeda Arzinda, Asif, Mohsin, Khan, Khurshid A., Siddique, Nasir, Khan, Aijaz Zeeshan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654232/ https://www.ncbi.nlm.nih.gov/pubmed/33200031 http://dx.doi.org/10.1016/j.amsu.2020.11.027 |
Ejemplares similares
-
“Tocilizumab-an option for patients with COVID-19 associated cytokine release syndrome: A single center experience”, a retrospective study-original article
por: Chachar, Aijaz Zeeshan Khan, et al.
Publicado: (2021) -
METHYLPREDNISOLONE VERSUS DEXAMETHASONE FOR TREATMENT OF SEVERE OR CRITICAL COVID-19: A QUASI-EXPERIMENTAL STUDY (MD TREAT)
por: Nasir, N., et al.
Publicado: (2023) -
Dexamethasone versus weight-adjusted methylprednisolone in patients with moderate-severe SARS-CoV-2 pneumonia
por: Aomar-Millán, Ismael F., et al.
Publicado: (2023) -
Role of hematological parameters in the stratification of COVID-19 disease severity
por: Taj, Sadia, et al.
Publicado: (2021) -
Dexamethasone/eltrombopag/methylprednisolone: Lack of efficacy: 2 case reports
Publicado: (2022)